Radiation dosimetry of florbetapir F 18

EJNMMI Research

Volumn 4, Issue 1, 2014, Pages

  Joshi, Abhinay D ^a   Pontecorvo, Michael J ^a   Adler, Lee ^b   Stabin, Michael G ^c   Skovronsky, Daniel M ^a,d   Carpenter, Alan P ^a   Mintun, Mark A ^a  

^a AVID RADIOPHARMACEUTICALS   (United States)

^b Adler Institute for Advanced Imaging   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLORBETAPIR F 18; TRACER;

ADULT; AMYLOID PLAQUE; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; FEMALE; GALLBLADDER; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; WHOLE BODY SCINTISCANNING;

EID: 84892506285     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-4-4     Document Type: Article

References (21)

1. The National Institute on Aging and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment Of Alzheimer's Disease: Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging 1997, 18:S1-S2.
2. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Långström BJ: Imaging brain amyloid in Alzheimer's disease with Pittsburg Compound-B. Ann Neurol 2004, 55:306-319.
3. Nordberg A, Rinne JO, Kadir A, Långström B: The use of PET in Alzheimer disease. Nat Rev Neurol 2010, 6(2):78-87.
4. Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Mathis CA: Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci 2001, 69(13):1471-1484.
5. Rowe CC, Villemagne VL: Brain amyloid imaging. J Nucl Med 2011, 52(11):1733-1740.
6. Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, Benedum TE, Kilbourn MR, Skovronsky D, Kung HF: Preclinical properties of 18F-AV-45: a PET agent for Aβ plaques in the brain. J Nucl Med 2009, 50:1887-1894.
7. Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, Dannals RF, Nandi A, Brasić JR, Ye W, Hilton J, Lyketsos C, Kung HF, Joshi AD, Skovronsky DM, Pontecorvo MJ: In vivo imaging of amyloid deposition in Alzheimer's disease using the novel radioligand 18F-AV-45 (florbetapir F 18). J Nucl Med 2010, 51(6):913-920.
8. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, Pontecorvo MJ, Hefti F, Carpenter AP, Flitter ML, Krautkramer MJ, Kung HF, Coleman RE, Doraiswamy PM, Fleisher AS, Sabbagh MN, Sadowsky CH, Reiman EP, Zehntner SP, Skovronsky DM, AV45-A07 Study Group: Use of florbetapir-PET for imaging β-amyloid pathology. JAMA 2011, 305(3):275-283.
9. Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, Fleisher AS, Reiman EM, Sabbagh MN, Sadowsky CH, Schneider JA, Arora A, Carpenter AP, Flitter ML, Joshi AD, Krautkramer MJ, Lu M, Mintun MA, Skovronsky DM, AV-45-A16 Study Group: Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol 2012, 11(8):669-678.
10. Rohen JK, Yokochi C: Color Atlas of Anatomy: A Photographic Study of the Human Body. 3rd edition. New York: Igaku-Shoin; 1992.
11. Netter FH: Atlas of Human Anatomy. Dover: Ciba-Geigy Corporation; 1989.
12. Foster DM, Barrett PHR: Developing and testing integrated multi-compartmental models to describe a single-input multiple-output study using the SAAM II software system. In Mathematical Modeling of Experimental Nutrition. Edited by Clifford AJ. New York: Plenum; 1998:59-78.
13. Stabin MG, Siegel JA: Physical models and dose factors for use in internal dose assessment. Health Phys 2003, 85:294-310.
14. Stabin MG, Sparks RB, Crowe E: OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005, 46:1023-1027.
15. International Commission on Radiological Protection: Radiation Dose to Patients from Radiopharmaceuticals. ICRP Publication 106: Addendum 3 to Publication 53. Oxford: Pergamon; 1998.
16. Lin KJ, Hsu WC, Hsiao IT, Wey SP, Jin LW, Skovronsky D, Wai YY, Chang HP, Lo CW, Yao CH, Yen TC, Kung MP: Whole-body distribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent-a pilot study. Nucl Med Biol 2010, 37:497-508.
17. Koole M, Lewis D, Buckley C, Nelissen N, Vandenbulcke M, Brooks D, Vandenberghe R, Van Laere K: Whole-body biodistribution and radiation dosimetry of 18F-GEo67: a radioligand for in vivo brain amyloid imaging. J Nucl Med 2009, 50:818-822.
18. O'Keefe G, Saunder TH, Steven Ng, Ackerman UWE, Tochon-Danguy HJ, Chan GJ, Gong S, Dyrk T, Lindemann S, Holl G, Dinkelborg L, Villemagne V, Rowe CC: Radiation dosimetry of β-amyloid tracers 11C-PIB and 18F-BAY94-9172. J Nucl Med 2009, 50:309-315.
19. Hays MT, Segall GM: A mathematical model for the distribution of fluorodeoxyglucose in humans. J Nucl Med 1999, 40:1358-1366.
20. Deloar HM, Fujiwara T, Shidahara M, Nakamura T, Watabe H, Narita Y, Itoh M, Miyake M, Watanuki S: Estimation of absorbed dose for 2-[F-18] fluoro-2-deoxy-D-glucose using whole-body positron emission tomography and magnetic resonance imaging. Eur J Nucl Med 1998, 25:565-574.
21. Mejia AA, Nakamura T, Masatoshi I, Hatazawa J, Masaki M, Watanuki S: Estimation of absorbed doses in humans due to intra-venous administration of fluorine-18- fluorodeoxyglucose in PET studies. J Nucl Med 1991, 32:699-706.